Pay in 4 interest-free payments of $5.90 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
The long-term storage of peptide solutions is not recommended, especially when the peptide contains Asn, Gln, Cys, Met, or Trp residues
Of note, it is imperative to be aware of the medication shortage for all GLP-1 RAs when prescribing these medications for patients with HS
Sharp declines have been observed in refrigerated salad dressings, dried meat snacks, and alcohol, according to Circana data
Clinical Trial Results STEP Trials (Semaglutide) The STEP program studied semaglutide 2.4 mg weekly in overweight/obese adults: STEP 1 : 16.9% average weight loss over 68 weeks vs 2.4% placebo STEP 2 (T2D patients): 9.6% weight loss STEP 3 (with behavioral therapy): 16.0% weight loss STEP 5 (2-year data): 15.2% sustained weight loss SURMOUNT Trials (Tirzepatide) The SURMOUNT program studied tirzepatide at 5mg, 10mg, and 15mg weekly: SURMOUNT-1 : 20.9% average weight loss at 15mg over 72 weeks vs 3.1% placebo SURMOUNT-2 (T2D patients): 14.7% at 15mg SURMOUNT-3 (with lifestyle intervention): 26.6% at highest dose SURMOUNT-4 (maintenance): continued weight loss vs weight regain on placebo Head-to-Head No large head-to-head trial has directly compared them at optimal doses for weight loss
US$ 22.41
US$ 26.61
US$ 24.71
